AIFA has finalised company-level liabilities for the 2025 direct-purchase medicines overspend, leaving the previously announced €2.385 billion total unchanged and triggering payment obligations.
The Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) has issued its final determination allocating €2,385,437,778 of 2025 pharmaceutical expenditure payback liabilities to individual manufacturers and regions. The decision, published on 29 October, follows consultation on preliminary calculations released in July.
The liability arises from expenditure exceeding the statutory ceiling for medicines purchased directly by public healthcare structures in 2025. Under the applicable rules, manufacturers bear a defined share of the excess, allocated using their relevant market shares. This is distinct from ordinary negotiated price rebates.
AIFA reports that observations received from companies did not lead to changes in the calculated liabilities or corresponding market shares. Determination No. 1531/2026 therefore converts previously published figures into final company-level allocations, rather than identifying a new or larger aggregate overspend.
The determination becomes effective on the day after publication of its notice in the Official Gazette. Companies must then make payments within 30 days, transferring the amounts due separately to each region and autonomous province according to the official allocation tables.
AIFA requires manufacturers to record payment evidence in its Spending-Pha system and send confirmations within the following three working days. The final determination establishes the immediate administrative payment step, while the separate legal questions surrounding Italy’s payback framework are not resolved by this allocation decision.
Source: Italian Medicines Agency
Link: Ripiano della spesa farmaceutica per acquisti diretti per l’anno 2025 (Payback of pharmaceutical expenditure for direct purchases in 2025)
Date: 29 October 2026
Source: Italian Medicines Agency
Link: Ripiano della spesa farmaceutica per acquisti diretti per l’anno 2025 – Avvio del procedimento – Pubblicazione dei dati (Direct-purchase pharmaceutical payback for 2025 – Commencement of the procedure and publication of data)
Date: 30 July 2026
Please accept {{cookieConsents}} cookies to view this content